Anthem (ANTX) Stock Price, News & Analysis

Company Overview

An2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs. An2 Therapeutics received regulatory designations intended to support development of the therapy, including Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration.

The company was founded in 2017 and was headquartered in Menlo Park, California. Eric Easom served as co-founder, president and chief executive officer. An2 Therapeutics announced that it was discontinuing development of epetraborole after results from its EBO-301 study did not support continued development. The company name provided does not match the Nasdaq symbol ANTX, which has been associated with An2 Therapeutics.

Key Stats

• Today's Range: $3.50 to $3.70
• 50-Day Range: $3.37 to $5.98
• 52-Week Range: $1.00 to $7.19
• Volume: 196,025 shs
• Average Volume: 309,524 shs
• Market Capitalization: $137.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Anthem Stock Analysis - MarketRank™

Anthem scored higher than 41% of companies evaluated by MarketBeat, and ranked 747th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Anthem has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Anthem has a consensus price target of $9.00, representing about 147.9% upside from its current price of $3.63.

Amount of Analyst Coverage

Anthem has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Anthem has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.89% of the float of Anthem has been sold short.

Short Interest Ratio / Days to Cover

Anthem has a short interest ratio ("days to cover") of 7.39.

Change versus previous month

Short interest in Anthem has recently increased by 15.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anthem does not currently pay a dividend.

Dividend Growth

Anthem does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.26

News Sentiment

Anthem has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Anthem this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Anthem insiders have sold 2,643.34% more of their company's stock than they have bought. Specifically, they have bought $11,602.00 in company stock and sold $318,282.00 in company stock.

Percentage Held by Insiders

22.61% of the stock of Anthem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.47% of the stock of Anthem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/27/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/09/2026
• 2026 Stifel Healthcare Conference: 11/10/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ANTX
• Previous Symbol: NASDAQ:ANTX
• CIK: 1156093
• Web: www.antheminc.com
• Phone: 650-331-9090
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Anthem: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +147.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.52%
• Return on Assets: -48.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.32
• Quick Ratio: 14.32

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 1.87

Miscellaneous

• Outstanding Shares: 37,740,000
• Free Float: 29,204,000
• Market Cap: $137.00 million
• Optionable: Optionable
• Beta: -0.98